THE WOODLANDS, Texas, Nov. 14, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that a new analysis evaluating the clinical benefit of Lexicon’s investigational ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback